Breaking News

OraSure, Thermo Fisher Enter Abuse Assays Pact

November 21, 2013

OraSure terminates assay collaboration with Roche Diagnostics

OraSure Technologies, Inc. has entered an agreement with Thermo Fisher Scientific to develop and supply as many as 12 homogenous fully automated oral fluid drugs of abuse assays for use with a new Intercept oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and certain other countries, subject to applicable regulatory approvals.
The companies anticipate selling NIDA-5 panel assays with the next generation Intercept device in the domestic criminal justice and forensics markets beginning in 2H14, and expect to complete development of several more assays and obtain FDA 510(k) clearance and approvals in certain foreign countries. The assays will be optimized to comply with new oral fluid guidelines expected to be issued by the Substance Abuse and Mental Health Services Administration (SAMHSA) for the federally regulated market and certain other markets that follow Federal drug testing guidelines.
In conjunction with the new agreement, OraSure has terminated its assay collaboration agreement with Roche Diagnostics. However, certain assays developed under that collaboration will remain available on a transitional basis for use with OraSure's existing Intercept collection device.
"The new agreement with Thermo Fisher is an important strategic development for our Substance Abuse Testing business," said Douglas A. Michels, president and chief executive officer of OraSure Technologies. "Combined with our new Intercept collector, we look forward to adding a complete menu of fully automated oral fluid drug assays to our customer offerings beginning in 2014."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important